6:12 PM
Dec 10, 2012
 |  BC Extra  |  Clinical News

Takeda reports MM data for MLN9708

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said once-weekly 4 mg oral MLN9708 plus Revlimid lenalidomide and dexamethasone met the primary endpoint in the Phase II portion of an open-label, dose-escalation Phase I/II trial to treat previously untreated multiple myeloma (MM)....

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >